Project description
European training network in translational research of glioblastoma
Glioblastoma (GBM) is a very aggressive and lethal brain cancer with 85% of patients dying within two years. Currently, there is no effective therapy for GBM and new treatment options are urgently required. The Marie Skłodowska-Curie Actions-funded GLIOTRAIN project will focus on the development of a European research training network of 14 organisations from 8 countries to train 15 creative young researchers. The objective of GLIOTRAIN is to discover new therapeutic strategies for GBM treatment, using next-generation sequencing, systems medicine, and integrative multi-omics to understand the disease resistance mechanisms. The project network will prepare a new generation of scientists to address translational research and clinical care of the GBM.
Objective
Glioblastoma (GBM) is the most frequent, aggressive and lethal of all brain tumours. It has a universally fatal prognosis with 85% of patients dying within two years. New treatment options and effective precision medicine therapies are urgently required. This can only be achieved by focused multi-sectoral industry-academia collaborations in newly emerging, innovative research disciplines. GLIOTRAIN will exploit the intractability of GBM to address European applied biomedical research training needs. The ETN, which comprises 9 beneficiaries and 14 partner organisations from 8 countries, will train 15 innovative, creative and entrepreneurial ESRs. The research objective of GLIOTRAIN is to identify novel therapeutic strategies for application in GBM, while implementing state of the art next generation sequencing, systems medicine and integrative multi-omics to unravel disease resistance mechanisms. Research activities incorporate applied systems medicine, integrative multi-omics leveraging state of the art platform technologies, and translational cancer biology implementing the latest clinically relevant models. The consortium brings together leading European and international academics, clinicians, private sector and not-for-profit partners across GBM fields of tumour biology, multi-omics, drug development, clinical research, bioinformatics, computational modelling and systems biology. Thus, GLIOTRAIN will address currently unmet translational research and clinical needs in the GBM field by interrogating innovative therapeutic strategies and improving the mechanistic understanding of disease resistance. The GLIOTRAIN ETN addresses current needs in academia and the private sector for researchers that have been trained in an environment that spans translational research, medicine and computational biology, and that can navigate confidently between clinical, academic and private sector environments to progress applied research findings towards improved patient outcomes.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesclinical medicineoncology
- medical and health scienceshealth sciencespersonalized medicine
- medical and health sciencesbasic medicineimmunologyimmunotherapy
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
Programme(s)
Funding Scheme
MSCA-ITN-ETN - European Training NetworksCoordinator
2 Dublin
Ireland
See on map
Participants (8)
70174 Stuttgart
See on map
1445 Strassen
See on map
9052 ZWIJNAARDE - GENT
See on map
75013 Paris
See on map
3015 GD Rotterdam
See on map
38302 Wolfenbuttel
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
4354 ESCH SUR ALZETTE
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
1831 DIEGEM
See on map
Partners (14)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
D02 H903 DUBLIN 2
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
Hackensack, NJ
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
70563 Stuttgart
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
38106 Braunschweig
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
75013 Paris
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
Argonay
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
1019 GM AMSTERDAM
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
3001 Leuven
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
3533 VB Utrecht
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
2342 DH Oegstgeest
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
WC2B 6AN London
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
30625 Hannover
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
4365 ESCH-SUR-ALZETTE
See on map
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
3000 Leuven
See on map